Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Weibo Corp (WB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Weibo Corp — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Weibo Corp trades at $7.7 (market cap $1.89B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 21.1× Weibo Corp's market cap, and Weibo Corp pays a 7.89% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | WB | |
|---|---|---|
Market Cap | $39.89B | $1.89B |
Sector | Health | Media |
52-Week High | $491.22 | $12.83 |
52-Week Low | $278.09 | $7.20 |
Enterprise Value | $38.15B | $1.16B |
Dividend Yield | — | 7.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Weibo (WB) trades at $7.72 with a bullish technical signal and strong valuation metrics, including a P/E of 5.41 and P/B of 0.49. Recent earnings missed estimates in three consecutive quarters, but the company maintains robust profitability with a 21.15% net income margin. A dividend of $0.61 was declared for H1 2026, supporting shareholder returns amid competitive pressures.
The stock presents value with deep undervaluation relative to cash flows and balance sheet strength, though user engagement challenges and rivalry from Douyin pose growth risks. Analyst consensus is mixed with 45% buy ratings, highlighting potential upside if execution improves, but investors face headwinds from China's regulatory environment and advertising volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Weibo Corp
Weibo is the largest social media platform in China. As of 2020, Weibo had 521 million monthly active users and 225 million daily active users, many of whom are drawn there by the millions of key opinion leaders in entertainment, sports, and business circles. Sina is the major shareholder, holding 44.7% of shares and with 70.8% voting power.
Read more on WB →
